Unbiased Quantitative Proteomics of Organoid Models of Pancreatic Cancer

Ronnie Ren Jie Low ^1,2,3, Ka Yee Fung ^1,2, Laura F Dagley ^1,2

⁰The Walter and Eliza Hall Institute of Medical Research, Parkville, VIC, Australia.

Methods in Molecular Biology +

|

July 25, 2024

View abstract on PubMed

Summary

Pancreatic cancer organoid models offer a new way to study this lethal disease. Researchers used these models to analyze the proteomic landscape, aiming to find new therapeutic targets for pancreatic ductal adenocarcinoma.

Area Of Science

Oncology
Cancer Biology
Proteomics

Background

Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal cancer with poor prognosis and limited treatment options.
The underlying mechanisms of PDAC initiation and progression remain poorly understood.
Current treatments lack robust biomarkers for guiding selection or monitoring response.

Purpose Of The Study

To establish and utilize a preclinical pancreatic ductal adenocarcinoma organoid model.
To explore the biological mechanisms driving PDAC.
To identify novel therapeutic targets through proteomic analysis.

Main Methods

Development of protocols for generating pancreatic ductal adenocarcinoma organoid models.
Application of organoid models to define the proteomic landscape of PDAC.
Proteomic analysis to characterize molecular features of PDAC.

Main Results

Successful generation of a preclinical PDAC organoid model.
Characterization of the proteomic landscape of pancreatic ductal adenocarcinoma.
Data provides a foundation for identifying potential therapeutic targets.

Conclusions

Organoid models are valuable tools for studying PDAC biology.
Proteomic profiling of PDAC organoids can reveal new therapeutic avenues.
Further research using these models may lead to improved diagnostics and treatments for pancreatic cancer.

Keywords:

FACs Model Organoid Pancreatic cancer Proteomics